Humanin
A mitochondrial-derived peptide investigated for cell protection and aging-related biology.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Not FDA-approved; there is no established human therapeutic indication.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
A mitochondrial-derived peptide investigated for cell protection and aging-related biology.
Not FDA-approved; there is no established human therapeutic indication.
Endogenous peptide levels and disease associations cannot establish benefit from administering a commercial vial.
Why It's Being Studied
- Mitochondrial signalling
- Cell survival
- Aging research
Mechanism of Action
Proposed mechanisms include receptor-mediated cytoprotection and inhibition of pro-apoptotic pathways, largely established in model systems.
Proposed mechanisms include receptor-mediated cytoprotection and inhibition of pro-apoptotic pathways, largely established in model systems. Endogenous peptide levels and disease associations cannot establish benefit from administering a commercial vial.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Mitochondrial signalling
- Cell survival
- Aging research
- Cell and animal research
Evidence Summary
Evidence is predominantly cellular or animal research, with human biomarker associations rather than established administration benefits.
Higher tiers carry more weight. Filled tiers have evidence for Humanin; tap to read it.
- Evidence is predominantly cellular or animal research, with human biomarker associations rather than established administration benefits.
1 cited sources.
- In-vitro study1
Preclinical evidence
- Evidence is predominantly cellular or animal research, with human biomarker associations rather than established administration benefits.
Reported Adverse Events in Research
- Human administration safety, long-term growth-signalling effects and product identity are not established.
Limitations of Current Evidence
- Endogenous peptide levels and disease associations cannot establish benefit from administering a commercial vial.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Humanin | Trofinetide | |
|---|---|---|
| Evidence grade | D — Preclinical Research | B — Moderate Human Evidence |
| Regulatory status | Research Use Only | FDA Approved for Specific Indication |
| Human data | No | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Cell and animal research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- In-vitro study
Humanin — in-vitro study